🧬 No. 17 | 3-Minute Risk News on Gene-Based Drugs [May 29, 2025] | Investment Slowdown / DMD Treatment Death / PepGen Abandons Program

Thank you for reading!
Pressing the 🩷 button is a huge encouragement!

📅 What day is it today?

Meat Day 🥩 Eat some meat and recharge your stamina!

🇺🇸 Topic 1 | Gene Therapy Investment Slows Down—Caution Toward Pipelines for Rare Diseases

• On March 21, Reuters reported that investment in gene therapy startups is on a downward trend.

• Concerns are growing regarding the commercial viability and safety of treatments for sickle cell disease and Duchenne muscular dystrophy (DMD).

• Companies like Pfizer and Bluebird Bio are also withdrawing funds, scaling back or canceling some programs.

🔗 Source:
https://www.reuters.com/business/healthcare-pharmaceuticals/gene-therapy-loses-luster-investors-eye-quicker-returns-weight-loss-drugs-2025-03-21/
(Published: March 21, 2025)

🧑‍⚕️ Topic 2 | Sarepta's Elevidys (DMD Treatment) Trial Halted—16-Year-Old Patient Dies of Liver Failure

• Elevidys is a gene therapy for Duchenne muscular dystrophy (DMD) developed by Sarepta.

• DMD is a hereditary disease that primarily affects boys, involves progressive muscle weakness, and has limited current treatment options.

• In a Phase II trial, a 16-year-old patient died of acute liver failure, leading the FDA to demand a review of safety data and suspend the trial.

🔗 Source:
https://www.reuters.com/business/healthcare-pharmaceuticals/sarepta-halts-three-studies-testing-gene-therapy-muscle-disorder-2025-04-04/
(Published: April 4, 2025)

🧪 Topic 3 | PepGen Abandons Development of RNA Therapy for DMD

• PepGen was developing a treatment using RNA technology to help DMD patients produce proteins that support muscles.

• They determined that the efficacy was insufficient for a clinical trial candidate and canceled the development program.

• RNA therapy is a mechanism for producing proteins within the body, but adjusting efficacy and long-term safety remain major challenges.

🔗 Source:
https://www.reuters.com/business/healthcare-pharmaceuticals/pepgen-discontinue-development-experimental-duchenne-therapy-shares-drop-2025-05-28/
(Published: May 28, 2025)

📅 What day is it tomorrow?

May 30th is Milk Day 🥛 Maintain your health with calcium intake!

■■■■■■■■■■■■■■■■■■■■■
🔬 Deep Dive Corner | For those with time
A deeper explanation that couldn't be fully covered in the main text.
Tips for understanding the mechanisms and implications of side effects💡
■■■■■■■■■■■■■■■■■■■■■

Challenges in gene therapy as highlighted by investment slowdowns and clinical trial halts

• Investor caution
  High costs and limited patient populations are directly linked to profitability concerns. A lack of accumulated safety data is a factor causing the withdrawal of next-generation development funding.

• Limitations of DMD treatment
  Duchenne muscular dystrophy is caused by a deficiency in the gene for a protein that builds muscle. Elevidys is an attempt to compensate for this deficiency, but the burden on the liver was greater than anticipated, leading to fatal side effects.

• Challenges of RNA therapy
  Technology that injects RNA to produce proteins within the body is a new option, but it has become clear that adjusting the degradation rate and the amount produced is difficult, often leading to overreactions or insufficient efficacy.

• Future points of caution
  All these treatments share the characteristic that 'once they enter the body, they cannot be stopped.' Small-scale, phased trials, enhanced safety monitoring, and transparent data disclosure are essential.

🔗 Sources:
https://www.reuters.com/business/healthcare-pharmaceuticals/gene-therapy-loses-luster-investors-eye-quicker-returns-weight-loss-drugs-2025-03-21/
(Published: March 21, 2025)
https://www.reuters.com/business/healthcare-pharmaceuticals/sarepta-halts-three-studies-testing-gene-therapy-muscle-disorder-2025-04-04/
(Published: April 4, 2025)
https://www.reuters.com/business/healthcare-pharmaceuticals/pepgen-discontinue-development-experimental-duchenne-therapy-shares-drop-2025-05-28/
(Published: May 28, 2025)

💬 HappyRuler Comment

While expectations for the success of new technologies are generally high,
the halts and discontinuations serve as a painful reminder that safety verification must be the top priority.

I will deliver more unmissable risk information next time.
Click here for the serial magazine👇